ScholarIQanswers from OpenAlex
CancerCare Manitoba
InstitutionResearch output, impact & collaborations
CancerCare Manitoba is a institution indexed in ScholarIQ from OpenAlex.
What is known about CancerCare Manitoba?
ScholarIQrecord summary
CancerCare Manitoba is a research organisation in Winnipeg, CA. OpenAlex records 4,289 works and 365,993 citations for it. 767 researchers list it as their most recent affiliation.
How many works does CancerCare Manitoba have?
ScholarIQindexed works
CancerCare Manitoba has 4,289 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does CancerCare Manitoba have?
ScholarIQcitation count
CancerCare Manitoba has 365,993 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at CancerCare Manitoba?
ScholarIQresearcher count
CancerCare Manitoba has 767 researchers in the ScholarIQ index.
What is the average h-index at CancerCare Manitoba?
ScholarIQavg h-index
CancerCare Manitoba has an average h-index of 67.2 in OpenAlex.
What is the ROR of CancerCare Manitoba?
ScholarIQror
The ROR for CancerCare Manitoba is on the source record.
What is the OpenAlex record for CancerCare Manitoba?
ScholarIQopenalex
The OpenAlex for CancerCare Manitoba is on the source record.
What is the Wikidata of CancerCare Manitoba?
ScholarIQwikidata
The Wikidata for CancerCare Manitoba is on the source record.
Who are the most-cited researchers behind CancerCare Manitoba?
ScholarIQtop researchers by citations
What are the most-cited papers on CancerCare Manitoba?
ScholarIQmost cited works
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin, Gulisa Turashvili, Oscar M. Rueda, Mark Dunning, Doug Speed, Andy G. Lynch, Shamith Samarajiwa, Yinyin Yuan, Stefan Gräf, Gavin Ha, Gholamreza Haffari, Ali Bashashati, Roslin Russell, Steven McKinney, Anita Langerød, Andrew R. Green, Elena Provenzano, Gordon Wishart, Sarah E. Pinder, Peter H. Watson, Florian Markowetz, Leigh C. Murphy, Ian O. Ellis, Arnie Purushotham, Anne‐Lise Børresen‐Dale, James D. Brenton, Simon Tavaré, Carlos Caldas, Samuel Aparício
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
Bernard Pereira, Suet‐Feung Chin, Oscar M. Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen‐John Sammut, Dana W.Y. Tsui, Bin Liu, Sarah‐Jane Dawson, Jean Abraham, Helen Northen, John F. Peden, Abhik Mukherjee, Gulisa Turashvili, Andrew R. Green, Steve McKinney, Arusha Oloumi, Sohrab P. Shah, Nitzan Rosenfeld, Leigh C. Murphy, David Bentley, Ian O. Ellis, Arnie Purushotham, Sarah E. Pinder, Anne‐Lise Børresen‐Dale, Helena Earl, Paul D.P. Pharoah, Mark T. Ross, Samuel Aparício, Carlos Caldas
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga
How much of the research on CancerCare Manitoba is open access?
ScholarIQopen access share
75%OPEN ACCESS